Ashfield Capital Partners, LLC Biogen Inc. Transaction History

Ashfield Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 29, 2019	SELL	$219.29 - $241.72 $223,456 - $246,312	-1,019 Closed	0 $0
Q1 2019 Apr 30, 2019	SELL	$216.71 - $338.96 $79,749 - $124,737	-368 Reduced 26.53%	1,019 $241,000
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $102,488 - $129,812	368 Added 36.11%	1,387 $417,000
Q2 2018 Jul 26, 2018	SELL	$257.52 - $306.91 $222,497 - $265,170	-864 Reduced 45.88%	1,019 $296,000
Q1 2018 May 02, 2018	SELL	$260.13 - $367.91 $74,137 - $104,854	-285 Reduced 13.15%	1,883 $516,000
Q4 2017 Feb 13, 2018	SELL	$307.64 - $344.58 $38,147 - $42,727	-124 Reduced 5.41%	2,168 $691,000
Q3 2017 Nov 07, 2017	SELL	$281.15 - $329.69 $33,738 - $39,562	-120 Reduced 4.98%	2,292 $718,000
Q2 2017 Aug 14, 2017	BUY	N/A	2,412	2,412 $655,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $23B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Ashfield Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Ashfield Capital Partners, LLC with notifications on news.